Can These Mutations Be Targeted for Cancer Therapy?
Yes, mutations in signaling pathways can be targeted for cancer therapy. Targeted therapies such as tyrosine kinase inhibitors (e.g., imatinib for BCR-ABL in chronic myeloid leukemia) and monoclonal antibodies (e.g., trastuzumab for HER2 in breast cancer) have shown significant efficacy. Additionally, inhibitors of specific pathway components, such as mTOR inhibitors and BRAF inhibitors, are being used to treat various cancers.
